Physician profile
Michael A Ellis
NPI 1003981671
$4,960.67
in general payments reported to CMS, 2019-2025
26 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $459 · 2021: $536 · 2022: $388 · 2023: $682 · 2024: $767 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.91 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $413.78 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Allergan, INC. | $402.80 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $377.73 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $375.88 | 2019-2022 | |
| Axsome Therapeutics, INC. | $349.95 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $311.24 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $304.57 | 2023-2025 | Caplyta |
| Alkermes, INC. | $278.19 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $253.66 | 2021-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $250.97 | 2019-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $152.42 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $143.96 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $132.64 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $113.39 | 2024-2025 | Cobenfy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $104.29 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $90.84 | 2019-2025 | Fanapt |
| Shire North American Group INC | $51.63 | 2019 | |
| Vertical Pharmaceuticals, LLC | $50.50 | 2025 | Relexxii |
| Neurocrine Biosciences, INC. | $41.91 | 2022-2024 | Ingrezza |
| Neos Therapeutics, LP | $40.75 | 2019-2022 | |
| Adlon Therapeutics L.P. | $40.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.42 | 2021 | |
| Noven Therapeutics, LLC | $19.08 | 2025 | Xelstrym |
| Tris Pharma INC | $15.79 | 2023 | Dyanavel Xr |
| Orexo US, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.